Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Stroke Cerebrovasc Dis ; 28(7): 1979-1986, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-30982718

RESUMO

BACKGROUND: Hemorrhagic infarction (HI) is among the most severe complications that can occur following the administration of intravenous recombinant tissue plasminogen activator (rt-PA). In the present study, we aimed to determine the optimal cut-off points of blood pressure (BP) for HI after rt-PA treatment, and to compare our findings with those for other prediction models. METHODS: We analyzed data from 109 consecutive patients with stroke treated at our hospital between 2009 and 2016. HI was confirmed via computed tomography or magnetic resonance imaging. Patients were classified into a symptomatic HI group, an asymptomatic HI group, and a non-HI group. BP was measured on admission and before rt-PA treatment. Glucose Race Age Sex Pressure Stroke Severity (GRASPS) and Totaled Health Risks in Vascular Events (THRIVE) scores were also calculated. Receiver operating characteristic (ROC) analysis was used to determine factors associated with symptomatic and asymptomatic HI. RESULTS: Among the 109 total patients, 25 patients developed symptomatic HI, while 22 patients developed asymptomatic HI. ROC analysis for predicting symptomatic and asymptomatic HI revealed that the area under the curve for pretreatment systolic BP (SBP) was .88 (95% confidence interval[CI]: .83-.94), while those for GRASPS and THRIVE scores were .75 (95% CI: .66-.85) and .69 (95% CI: .59-.79), respectively. We identified an optimal cut-off point of 160 mm Hg (sensitivity: 82.3%; specificity: 76.6%; diagnostic accuracy: 80.0%; positive predictive value: 76.6%; negative predictive value: 82.5%). CONCLUSIONS: Pre-treatment SBP may be a simple predictor of symptomatic and asymptomatic HI in patients with stroke undergoing rt-PA treatment.


Assuntos
Pressão Sanguínea , Fibrinolíticos/efeitos adversos , Hemorragias Intracranianas/induzido quimicamente , Acidente Vascular Cerebral/tratamento farmacológico , Terapia Trombolítica/efeitos adversos , Ativador de Plasminogênio Tecidual/efeitos adversos , Idoso , Idoso de 80 Anos ou mais , Feminino , Fibrinolíticos/administração & dosagem , Humanos , Infusões Intravenosas , Hemorragias Intracranianas/diagnóstico por imagem , Hemorragias Intracranianas/fisiopatologia , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes/efeitos adversos , Sistema de Registros , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Acidente Vascular Cerebral/diagnóstico , Acidente Vascular Cerebral/fisiopatologia , Ativador de Plasminogênio Tecidual/administração & dosagem , Tomografia Computadorizada por Raios X , Resultado do Tratamento
2.
Rinsho Shinkeigaku ; 59(3): 139-143, 2019 Mar 28.
Artigo em Japonês | MEDLINE | ID: mdl-30814445

RESUMO

A 52-year old woman first noted dysphagia four months before admission followed by dysarthria two months later. She then developed weakness of all limbs and became unable to walk. All these symptoms, associated with tongue atrophy, slowly progressed, leading to the initial clinical impression of a motor neuron disease, although her nerve conduction study and electromyography showed no abnormalities. Her brain MRI with T2 weighted/diffusion weighted image (DWI)/fluid attenuated inversion recovery (FLAIR) revealed a high signal lesion located at dorsal medulla oblongata. She proved positive for anti-aquaporin 4 antibody, which confirmed the diagnosis of neuromyelitis optica spectrum disorders (NMOSD). We conclude that NMOSD may initially present with progressive bulbar palsy and pyramidal tract disorder over a few months, mimicking a motor neuron disease. Awareness of this atypical presentation helps establish an early diagnosis of this treatable entity.


Assuntos
Paralisia Bulbar Progressiva/diagnóstico , Paralisia Bulbar Progressiva/etiologia , Doença dos Neurônios Motores , Neuromielite Óptica/complicações , Neuromielite Óptica/diagnóstico , Aquaporina 4/imunologia , Atrofia/etiologia , Autoanticorpos/sangue , Biomarcadores/sangue , Encéfalo/diagnóstico por imagem , Diagnóstico Diferencial , Progressão da Doença , Disartria/etiologia , Feminino , Humanos , Imageamento por Ressonância Magnética , Pessoa de Meia-Idade , Fatores de Tempo , Língua/patologia
3.
Rinsho Shinkeigaku ; 58(11): 663-667, 2018 Nov 28.
Artigo em Japonês | MEDLINE | ID: mdl-30369522

RESUMO

A 33-year-old man admitted to our hospital for the evaluation of progressive muscular atrophy of his left lower leg. From his childhood, he had suffered from transient attacks of limb paralysis and myalgia lasting about 1 hour. At age 30, the muscle weakness and atrophy of his left lower leg emerged and progressed gradually. Muscle MR images showed atrophy and fat replacement in left lower leg, and muscle biopsy revealed tubular aggregates (TA). Genetic analysis showed heterozygous c.2111C>T/p.T704M missense mutation of SCN4A gene, which causes hyperkalemic periodic paralysis (HyperPP). Although HyperPP is rare, it is quite critical for clinicians to recognize that the patients of HyperPP often present progressive myopathy. We emphasize the importance of paying attention to progressive myopathy and discuss the pathological mechanism of myopathy through this case report.


Assuntos
Hiperpotassemia/complicações , Hiperpotassemia/diagnóstico , Miopatias Congênitas Estruturais/etiologia , Paralisia/complicações , Paralisia/diagnóstico , Periodicidade , Adulto , Progressão da Doença , Heterozigoto , Humanos , Hiperpotassemia/genética , Imageamento por Ressonância Magnética , Masculino , Músculo Esquelético/diagnóstico por imagem , Músculo Esquelético/patologia , Mutação , Miopatias Congênitas Estruturais/diagnóstico por imagem , Miopatias Congênitas Estruturais/patologia , Canal de Sódio Disparado por Voltagem NAV1.4/genética , Paralisia/genética , Linhagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA